Atumelnant
In Development
Vertex Pharmaceuticals
Overview
An oral pipeline candidate for endocrine disease acquired with Crinetics Pharmaceuticals, part of the endocrinology pipeline Vertex and Crinetics said could reach $5B+ in combined peak annual sales alongside Palsonify.
Joined Vertex's pipeline when the Crinetics acquisition closed on September 1, 2026; clinical stage and timelines to be detailed as Vertex integrates the endocrinology business.